Univest
Univest
  • Markets
  • 3 Branded Generics Marketer, Cardiovascular and CNS Leader and Paracetamol and Metformin Ingredients Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India

    • October 26, 2026
    • Posted by: Chaitanya Auti
    • Category: Best Stocks
    No Comments
    3 Branded Generics Marketer, Cardiovascular and CNS Leader and Paracetamol and Metformin Ingredients Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India

    Branded Generics and API Pharma Stocks with a strong future roadmap: Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.

    read more
  • 3 Pain and Anti-Malarial Brands, Branded Generics Marketer and Global Generics and Specialty Franchise Stocks With a Strong Future Roadmap: Ipca Laboratories, Emcure Pharmaceuticals and Lupin

    • October 23, 2026
    • Posted by: Chaitanya Auti
    • Category: Best Stocks
    No Comments
    3 Pain and Anti-Malarial Brands, Branded Generics Marketer and Global Generics and Specialty Franchise Stocks With a Strong Future Roadmap: Ipca Laboratories, Emcure Pharmaceuticals and Lupin

    Pain Care and Specialty Generics Stocks with a strong future roadmap: Ipca Laboratories, Emcure Pharmaceuticals and Lupin. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.

    read more
  • 3 Branded Generics, Fermentation-Based Ingredients and Latin America Generics Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Concord Biotech and Caplin Point Laboratories

    • October 22, 2026
    • Posted by: Ankit Jaiswal
    • Category: Best Stocks
    No Comments
    3 Branded Generics, Fermentation-Based Ingredients and Latin America Generics Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Concord Biotech and Caplin Point Laboratories

    Branded Generic and Ingredient Stocks with a strong future roadmap: Emcure Pharmaceuticals, Concord Biotech and Caplin Point Laboratories. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.

    read more
  • 3 Oncology Generics, Branded Generics and Biologics Platform Stocks With a Strong Future Roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare

    • October 21, 2026
    • Posted by: Kunal Singla
    • Category: Best Stocks
    No Comments
    3 Oncology Generics, Branded Generics and Biologics Platform Stocks With a Strong Future Roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare

    Specialty Generics and Oncology Stocks with a strong future roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.

    read more
  • 3 Global Generics, Branded Generics and Contract Formulations Stocks With a Strong Future Roadmap: Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab

    • October 21, 2026
    • Posted by: Chaitanya Auti
    • Category: Best Stocks
    No Comments
    3 Global Generics, Branded Generics and Contract Formulations Stocks With a Strong Future Roadmap: Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab

    Generic and Branded Pharma Stocks with a strong future roadmap: Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.

    read more
  • 3 Hospital Pharma, Generic Formulations and Domestic Brands Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma

    • October 21, 2026
    • Posted by: Neeraj Pandey
    • Category: Best Stocks
    No Comments
    3 Hospital Pharma, Generic Formulations and Domestic Brands Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma

    Formulation Pharma Stocks with a strong future roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.

    read more
  • 1
  • 2